@article{5881c3cc397c4ce0a7810c95cdc02a3b,
title = "Unruptured brain AVMs: to treat or not to treat",
author = "Brown, {Robert D.}",
note = "Funding Information: Should all unruptured AVMs be treated aggressively on a routine basis? The study by Wedderburn and colleagues 6 and those from other population-based or referral populations cannot answer this question definitively. Random allocation of patients with unruptured AVMs in a clinical trial continues to be controversial, with compelling arguments both for and against. 8,9 Efforts to randomly assign selected patients with AVMs—those for whom clinical equipoise exists—to the best treatment compared with natural history should be supported. A Randomized trial of Unruptured Brain AVMs ( ARUBA ) has been funded by the US National Institutes of Health. The cerebrovascular community looks forward to the successful completion of this study, along with the necessary long-term follow-up. Until then, our patients will continue to be managed on the basis of reviews and guidelines, 10,11 natural history data, 3 and data from non-randomised populations. All of these are of interest but, unfortunately for our patients, not the final answer. ",
year = "2008",
month = mar,
doi = "10.1016/S1474-4422(08)70027-9",
language = "English (US)",
volume = "7",
pages = "195--196",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Lancet Publishing Group",
number = "3",
}